Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Precision Medicine Initiative Aims High But Must Surmount Technical, Practical Hurdles

Executive Summary

White House proposal for a longitudinal cohort encompassing one million people seeks to leverage ongoing studies. But bringing all that data together under one roof, and ensuring it is useful and participants’ privacy is adequately protected, promises to be a significant task.

You may also be interested in...



‘Precision Medicine’ Gets R&D Funding Push In President’s Speech

President Obama highlights potential for personalized medicine in his State of the Union address and will seek a “major increase” in research and development funding.

Lung-MAP Patient Screening Should Translate To Cost-Savings

Sponsors say the large number of biomarkers that will be searched for in candidates for the lung cancer trial should allow researchers to find patients much faster, and will offer cost-savings over traditional drug development.

Amylyx Relyvrio: Pricing, Compounding, And The Shadow Of Makena

The new ALS product is a fixed-dose combo of two ingredients – sodium phenylbutyrate and taurursodiol – that some patients currently are compounding. Amylyx says it will explore ‘all options’ in addressing that, noting its strong IP for Relyvrio, but also committing to access.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056642

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel